The gene encoding the LDL receptor is located on chromosome 19p13. To date, more than 1000 mutations have been identified. 13 Inheritance of FH is usually autosomal dominant, which means that 50% of first-degree relatives of people with FH are at risk of having the dis- by 100-fold. 14 In those individuals with heterozygous FH who are not treated, approximately 50% of men and 30%
of women experience cardiovascular events by age 60. 15 Without treatment, an estimated 50% of individuals with FH will survive to age 60 years and 20% will survive to age 70 years. 16 There is a misconception that FH is rare. 17 Rather, FH is the most common monogenetic disorder in Europe and the United States. 9 Although homozygous FH is indeed Although statins are typically effective in the prevention of cardiovascular events in individuals with FH, some patients do not respond to or are intolerant of statins. For these individuals, LDL apheresis is now available as an alternative to pharmacotherapy.
The purpose of the present review is to update physicians on the current guidelines for the screening, diagnosis, and management of FH.
Pathophysiologic Processes, Genetics, and Prevalence
In individuals with normal lipid metabolism, the LDL receptor binds to apolipoprotein B on the LDL particle and removes LDL cholesterol from the peripheral circulation. 12 In individuals with FH, however, the function of
KEY POINTS
Familial hypercholesterolemia is the most common monogenetic disorder in Europe and the United States. The incidence of heterozygous familial hypercholesterolemia is 1:500 in the general population. For individuals with the disorder who are left untreated, the risk of premature cardiovascular disease is increased by 100-fold. Without treatment, approximately 50% will survive to age 60 years.
All family members of patients with familial hypercholesterolemia should be screened. Children of patients with familial hypercholesterolemia should be screened with fasting lipid profile or nonfasting non-high-density lipoprotein cholesterol beginning at age 2 or 3 years. Universal screening of all children is recommended at age 9 to 11 years, regardless of family history.
Statins are considered first-line therapy for patients with familial hypercholesterolemia. Additional lipidlowering medications can be used in combination with statins to achieve therapeutic goals. Lowdensity lipoprotein apheresis is a treatment option for patients who do not respond to or are intolerant of maximal drug therapy.
genetic testing, and a "probable diagnosis" is made if there are elevated cholesterol levels and family history of a total cholesterol level of more than 290 mg/dL or premature cardiovascular disease. Image of tendon xanthoma, a pathognomonic physical examination finding in patients with familial hypercholesterolemia.
not be used to rule out the diagnosis. 7 However, because serum lipid testing is readily available, family history is straightforward and easy to obtain, and genetic testing is costly and often not covered by insurers, we favor the use of the MEDPED criteria as the initial tool to diagnose FH in the majority of patients at risk. Genetic testing may then be used to confirm the diagnosis in patients in whom the diagnosis is unclear.
Irrespective of which diagnostic criteria are used, it is advised that children of those with heterozygous FH be screened beginning at age 2 or 3 years. 7, 9, 11 In addition,
The National Lipid Association recommends universal Genetic testing is included in the Simon Broome and the Dutch Lipid Clinic Network but not the MEDPED criteria. Deoxyribonucleic acid, or DNA, analysis may detect 90% of currently identified LDL receptor mutations. 13 Genetic testing can be useful in distinguishing between FH and other types of inherited dyslipidemia, such as familial combined hyperlipidemia. 13 Genetic testing may also be helpful in family counseling. Although genetic testing can be useful for diagnosing FH and initiating appropriate therapy earlier, it should be noted that not every mutation has been identified and negative genetic testing should therefore FH who had established coronary heart disease, an approximate 25% reduction in coronary heart disease mortality was observed. 15 There was a greater reduction in coronary heart disease mortality in women than in men. 15 
Additional Drug Therapy
Many patients do not achieve recommended LDL cholesterol targets with statin monotherapy alone. In these patients, additional LDL-lowering agents are necessary. 9, 11 Drugs that decrease gastrointestinal absorption of cholesterol, including bile acid sequestrants and ezetimibe, are especially effective when combined with statin therapy. Bile acid sequestrants lower LDL cholesterol levels an additional 10% to 30% beyond statin therapy alone. 9 The use of bile acid sequestrants, however, is often limited by gastrointestinal and other side effects.
Colesevelam is a newer bile acid sequestrant that may be more effective and better tolerated than traditional bile acid sequestrants. 9 Bile acid sequestrants can affect ab- 
